Research Article

Short-Term Results of Switch from Conbercept to Bevacizumab or Ranibizumab in Eyes with Persistent Neovascular Age-Related Macular Degeneration

Figure 2

Changes of mean CMT in eyes with persistent nAMD. The mean CMT decreased significantly from T0 to T1 () followed by no further regression. But after switching to IVR or IVB, it decreased significantly from 294.9 ± 121.8 μm at T2 to 230.9 ± 107.0 μm at T3 and 220.4 ± 105.4 μm at T4. No significant difference was found between IVR and IVB subgroups for the mean decrease of CMT from T2 to T3 () and T4 (). CMT, central macular thickness; IVC, intravitreal injections of conbercept; IVB, intravitreal injection of bevacizumab; IVR, intravitreal injection of ranibizumab; T0, baseline visit; T1, 1 month after the first ICV; T2, 1 month after 3 monthly IVC; T3, 1 month after the first IVR or IVB; T4, 1 month after the last IVR or IVB.